Skip Navigation Links
About This Site   Contact Us   Help   
Sign In
< Back

Printable View  |  E-mail a Link

 August 2014 Update


New and Revised English Titles
Respiratory Syncytial Virus

AAP Featured News
In a policy statement published in the August 2014 Pediatrics, "Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection," and an accompanying technical report, both published online July 28, the American Academy of Pediatrics (AAP) revises its recommendations for use of palivizumab for respiratory syncytial virus (RSV).

The updated recommendation targets the infants most likely to benefit from palivizumab prophylaxis based on a comprehensive review of the literature, which is included in the technical report.

© 2006-2014 COPYRIGHT AMERICAN ACADEMY OF PEDIATRICS, ALL RIGHTS RESERVED Site map | Contact us | Privacy statement | About us | Home
American Academy of Pediatrics, 141 Northwest Point Blvd., Elk Grove Village, IL, 60007, 847-434-4000
Use of this Web site signifies acceptance of our Terms of Use